Back to Results
First PageMeta Content
Medicine / Endocrine system / Eli Lilly and Company / Insulin glargine / Pharmacology / Sanofi / New Drug Application / Insulin / Food and Drug Administration / Biology / Peptide hormones / Recombinant proteins


PRESS RELEASE FDA Accepts Sanofi’s New Drug Application for Basal Insulin Toujeo® – Toujeo dossier already accepted by EMA – Paris, France – July 8, 2014 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today
Add to Reading List

Document Date: 2014-07-08 00:57:36

Open Document

File Size: 39,43 KB

Share Result on Facebook

City

New York / Paris / /

Company

Sanofi / Genzyme / /

Country

France / United States / /

/

Event

FDA Phase / Company Listing Change / /

IndustryTerm

therapeutic solutions / consumer healthcare / healthcare / diabetes solutions / /

MedicalCondition

Global Diabetes / broad and diverse diabetes / diabetes / /

Organization

European Medicines Agency / U.S. Food and Drug Administration / FDA / European Union / /

Person

Pierre Chancel / Susan Brooks / Sébastien Martel / Jack Cox / /

/

Position

Senior Vice President / Global Diabetes / global healthcare leader / /

Product

Basal Insulin Toujeo® / U300 / Toujeo® / /

Technology

therapeutic solutions / /

SocialTag